Savara (NASDAQ:SVRA) Rating Reiterated by HC Wainwright

Savara (NASDAQ:SVRA)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They currently have a $10.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 156.41% from the stock’s previous close.

SVRA has been the subject of a number of other reports. Guggenheim raised their target price on Savara from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Oppenheimer boosted their target price on shares of Savara from $11.00 to $15.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 26th. Finally, JMP Securities reiterated a “market outperform” rating and set a $9.00 target price on shares of Savara in a research report on Monday, September 9th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $11.17.

Savara Trading Down 2.3 %

Shares of SVRA stock opened at $3.90 on Tuesday. The company has a market capitalization of $538.94 million, a P/E ratio of -10.54 and a beta of 0.97. Savara has a 12-month low of $3.12 and a 12-month high of $5.70. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26. The firm has a 50-day moving average price of $4.31 and a 200 day moving average price of $4.45.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). Research analysts forecast that Savara will post -0.44 earnings per share for the current fiscal year.

Institutional Trading of Savara

A number of institutional investors have recently bought and sold shares of the business. Superstring Capital Management LP acquired a new stake in shares of Savara during the fourth quarter worth $3,827,000. Wellington Management Group LLP acquired a new position in shares of Savara during the 4th quarter worth about $9,683,000. Sivia Capital Partners LLC bought a new stake in shares of Savara in the 4th quarter valued at about $169,000. China Universal Asset Management Co. Ltd. raised its position in shares of Savara by 66.3% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 26,035 shares of the company’s stock valued at $130,000 after acquiring an additional 10,381 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in Savara by 92.3% during the 1st quarter. BNP Paribas Financial Markets now owns 73,494 shares of the company’s stock worth $366,000 after acquiring an additional 35,269 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.